Business Context and Reporting Period
This Form 6-K filing by GSK plc reports the results of its 23rd Annual General Meeting (AGM) held on May 3, 2023. The meeting was conducted as a hybrid event at the Sofitel Hotel in Terminal 5 Heathrow, allowing for both in-person and virtual participation.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document focuses exclusively on corporate governance and shareholder voting outcomes rather than financial performance data.
Material Changes and Voting Results
Shareholders voted on 23 resolutions. Key outcomes include:
- Annual Report Adoption: Resolution 1 to receive and adopt the 2022 Annual Report passed with 99.05% of votes cast in favor.
- Remuneration Report: Resolution 2 to approve the Annual Report on Remuneration passed with 88.84% support, representing the highest opposition among standard resolutions.
- Board Elections: All director elections (Resolutions 3-13) passed with significant majorities. Notable results include the re-election of Dame Emma Walmsley (99.74% for) and the election of new directors Julie Brown (99.59% for) and Dr. Vishal Sikka (99.69% for). Urs Rohner received the lowest support among directors at 91.58%.
- Auditor Approval: The re-appointment of the auditor (Resolution 14) passed with 99.86% support.
- Shareholder Authorities: Special resolutions regarding share allotment, disapplication of pre-emption rights, and share buyback authority all passed with support ranging from 94.08% to 98.36%.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, or contingencies. The document serves as a record of the AGM proceedings and voting tallies.
Important Facts for Investors to Verify
- Verify the full text of the 2022 Annual Report and Remuneration Report referenced in the voting resolutions.
- Review the specific terms of the new Directors' Remuneration Policy approved under Resolution 16.
- Confirm the details of the share buyback authority and pre-emption rights disapplication granted under Resolutions 19, 20, and 21.
- Note the participation rate: 70.26% of issued share capital (excluding Treasury Shares) was represented by votes cast or withheld.